127 related articles for article (PubMed ID: 34999392)
1. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392
[TBL] [Abstract][Full Text] [Related]
2. Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Int Immunopharmacol; 2021 Nov; 100():108087. PubMed ID: 34464888
[TBL] [Abstract][Full Text] [Related]
3. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
5. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.
Al-Saraireh YM; Alshammari FOFO; Satari AO; Al-Mahdy YS; Almuhaisen GH; Abu-Azzam OH; Uwais AN; Abufraijeh SM; Al-Kharabsheh AM; Al-Dalain SM; Al-Qtaitat A; Al-Tarawneh F; Al Shuneigat JM; Al-Sarayreh SA
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143940
[TBL] [Abstract][Full Text] [Related]
7. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
8. CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer.
Yang X; Hutter M; Goh WWB; Bureik M
Curr Pharm Des; 2017; 23(14):2060-2064. PubMed ID: 28176668
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy.
Adamus G; Champaigne R; Yang S
Clin Immunol; 2020 Jan; 210():108317. PubMed ID: 31770612
[TBL] [Abstract][Full Text] [Related]
10. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women.
Frenkel K; Karkoszka J; Glassman T; Dubin N; Toniolo P; Taioli E; Mooney LA; Kato I
Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):49-57. PubMed ID: 9456243
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.
Lou N; Zheng C; Wang Y; Liang C; Tan Q; Luo R; Zhang L; Xie T; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jan; 72(1):235-247. PubMed ID: 35831618
[TBL] [Abstract][Full Text] [Related]
12. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
13. Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor.
Ladd J; Lu H; Taylor AD; Goodell V; Disis ML; Jiang S
Colloids Surf B Biointerfaces; 2009 Apr; 70(1):1-6. PubMed ID: 19157807
[TBL] [Abstract][Full Text] [Related]
14. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.
Liu W; Wang P; Li Z; Xu W; Dai L; Wang K; Zhang J
Scand J Immunol; 2009 Jan; 69(1):57-63. PubMed ID: 19140877
[TBL] [Abstract][Full Text] [Related]
16. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
17. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
19. Multicenter study on TGPO autoantibody prevalence in various thyroid and non-thyroid diseases; relationships with thyroglobulin and thyroperoxidase autoantibody parameters.
Estienne V; Duthoit C; Costanzo VD; Lejeune PJ; Rotondi M; Kornfeld S; Finke R; Lazarus JH; Feldt-Rasmussen U; Franke WG; Smyth P; D'Herbomez M; Conte-Devolx B; Persani L; Carella C; Jourdain JR; Izembart M; Toubert ME; Pinchera A; Weetman A; Sapin R; Carayon P; Ruf J
Eur J Endocrinol; 1999 Dec; 141(6):563-9. PubMed ID: 10601957
[TBL] [Abstract][Full Text] [Related]
20. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
